palms are sweaty, page-31

My apologies if this is re-covering already discussed topics but why has shareholder sentiment changed so drastically to the negative?

My simple reading going into the AdCom was that in previous communication the FDA indicated while not a usual requirement for new drug approvals (standard procedure for the US market is to meet or exceed current alternatives available), QRX would need to show safety and efficacy improvements due to it combining to existing drugs from the same category. The FDA encouraged QRX to expand on its findings from Study 22 which while having comparable side affects in some areas, showed a marked improvement in the issue of oxygen de-saturation in the blood. Bo ticked if successful.

This is what will be presented as I understood?

The idea of comparing MoxDuo IR to the Zohydro debate i felt was far fetched in so far as it is comparing an immediate release drug against a controlled release and the debate in the States was revolving around reforms in abuse deterrents for the later?

These aren't facts, this is what I understood and after following QRX for the last 2 years it was always known that it was a speculative share with high gains if successful..

What has happened recently to change sentiment so drastically? Is it nerves getting the better of investors or has there been a release I am not aware of? Any help appreciated!